We want to improve life after heart attack. More than 600,000 survivable heart attacks occur yearly in the US. That’s one heart attack every 40 seconds.
Menu
OUR MISSION
Prolifagen is a preclinical spin-out of University of Pennsylvania developing a medicine for cardiac regeneration based on microRNA technology.
Our management team holds essential complementary skill sets in differing areas of domain expertise and bring decades of experience to this work.
microRNA 302 drives proliferation of resident adult cardiac muscle cells in injured hearts, leading to reconstitution of functional heart muscle.
We want to improve life after heart attack. More than 600,000 survivable heart attacks occur yearly in the US. That’s one heart attack every 40 seconds.
Twenty percent of those (linked to larger infarcts) will lead to Heart Failure characterized by impaired heart pumping capacity. This is because hearts with large injuries undergo remodeling during the weeks and months after infarct and develop hypertrophy.